ADRENOMED
Adrenomed is a privately-financed, clinical-stage biopharmaceutical company with a clear mission: to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. The Company’s lead product candidate is Adrecizumab, a clinical-stage, first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity to treat life-threatening conditions associated with increased vascul... ar leakage, congestion and shock. their unique treatment approach combines the therapeutic antibody with a specific diagnostic, which uses Adrenomedullin as the biomarker to identify patients. The most important target indications are sepsis and septic shock as well as acute heart failure. Adrenomed’s business is effectively secured by a strong IP position with granted patents in all major markets. Adrenomed is based in Hennigsdorf near Berlin, Germany.
ADRENOMED
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2009-01-01
Address:
Berlin, Berlin, Germany
Country:
Germany
Website Url:
http://www.adrenomed.com
Total Employee:
11+
Status:
Active
Contact:
+49 (0) 3302 20 77 8 0
Email Addresses:
[email protected]
Total Funding:
49.11 M EUR
Technology used in webpage:
Lorem Ipsum IONOS
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Basilea Pharmaceutica
Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company.
BioVersys
BioVersys is a privately held Swiss biopharmaceutical company.
Cobra Biologics
Cobra Biologics is providing a biologics and pharmaceuticals service.
Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
Cytovation
Cytovation AS is a privately-held biotech company, specialising .
Hope Medicine
Hope Medicine is a science-driven clinical stage biopharmaceutical company
Molecular Partners
Molecular Partners is a clinical-stage biopharmaceutical company.
Novaremed AG
Novaremed AG is a clinical-stage Swiss biopharmaceutical company.
Current Employees Featured
Founder
Investors List
HBM Healthcare Investments
HBM Healthcare Investments investment in Convertible Note - Adrenomed
HBM Healthcare Investments
HBM Healthcare Investments investment in Convertible Note - Adrenomed
HBM Partners
HBM Partners investment in Convertible Note - Adrenomed
HBM Healthcare Investments
HBM Healthcare Investments investment in Convertible Note - Adrenomed
Wellington Partners
Wellington Partners investment in Series E - Adrenomed
HBM Healthcare Investments
HBM Healthcare Investments investment in Series E - Adrenomed
HBM Healthcare Investments
HBM Healthcare Investments investment in Convertible Note - Adrenomed
HBM Healthcare Investments
HBM Healthcare Investments investment in Series D - Adrenomed
HBM Healthcare Investments
HBM Healthcare Investments investment in Series D - Adrenomed
Wellington Partners
Wellington Partners investment in Series D - Adrenomed
Key Employee Changes
| Date | New article |
|---|---|
| 2023-02-01 | Adrenomed appoints Dr. Stephan Witte as Chief Medical Officer |
| 2022-07-12 | Adrenomed appoints David Germonpré as Chief Financial Officer |
| 2022-06-23 | Adrenomed appoints Dr. med. Steffen Stürzebecher as Chief Medical Officer |
Official Site Inspections
http://www.adrenomed.com
- Host name: 217-160-0-40.elastic-ssl.ui-r.com
- IP address: 217.160.0.40
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Adrenomed"
Adrenomed - Crunchbase Company Profile & Funding
Adrenomed is a privately-financed, clinical-stage biopharmaceutical company …See details»
Adrenomed Supervisory Board appoints Dr. Richard Jones as CEO
Mar 15, 2022 Richard Jones joins Adrenomed from Fusion Antibodies Plc, a contract research organization specialized in antibody engineering. As CEO of Fusion Antibodies Plc, Richard …See details»
Adrenomed - Financial Details - Crunchbase
Adrenomed is a privately-financed, clinical-stage biopharmaceutical company.See details»
News – Adrenomed
Feb 1, 2023 Adrenomed to attend San Francisco industry and investor conferences Hennigsdorf/Berlin (Germany), December 13, 2023 – Adrenomed AG, the vascular integrity …See details»
AdrenoMed AG - Drug pipelines, Patents, Clinical trials - Synapse
May 7, 2025 Explore AdrenoMed AG with its drug pipeline, therapeutic area, technology platform, 5 clinical trials, 12 news, Technology Platform:Monoclonal antibody, …See details»
2025 – Adrenomed
Oct 13, 2022 2025 Journal of Critical Care publishes positive results from prespecified, biomarker-guided subgroup analysis of AdrenoMed’s Phase II AdrenOSS-2 trial in septic shockSee details»
AdrenoMed AG (AdrenoMed AG) - 药物管线_专利_临床 …
May 7, 2025 Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in …See details»
Adrenomed 2025 Company Profile: Valuation, Funding & Investors …
Information on valuation, funding, cap tables, investors, and executives for Adrenomed. Use the PitchBook Platform to explore the full profile.See details»
Adrenomed Company Profile - Office Locations, Competitors
Adrenomed has 5 employees at their 1 location and $27.23 m in total funding,. See insights on Adrenomed including office locations, competitors, revenue, financials, executives, …See details»
Adrenomed - News & Analysis - Crunchbase
Jan 9, 2025 Adrenomed is a privately-financed, clinical-stage biopharmaceutical company.See details»
AdrenoMed Receives FDA Fast Track Designation for Enibarcimab …
Apr 10, 2024 AdrenoMed’s CEO Dr. Richard Jones commented: “We are very pleased that enibarcimab has received Fast Track designation from the FDA, recognizing its potential as an …See details»
Adrenomed AG | HBM Partners
Adrenomed is a privately-financed, clinical-stage biopharmaceutical company with a clear mission: to rescue vascular integrity in order to save the lives of critically ill patients with limited …See details»
Adrenomed (AdrenoMed AG) - startbase.com
Adrenomed erhält 22 Mio. Euro für Sepsis-Forschung Die Adrenomed AG treibt mit frischem Geld ihrer Investoren die Entwicklung des Produktkandidaten Adrecizumab voran.See details»
Adrenomed AG | LinkedIn
Adrenomed AG | 2.182 Follower:innen auf LinkedIn. An innovative biomarker-guided precision medicine solution for patients in acute care with sepsis and septic shock | Adrenomed AG is a …See details»
2020 – Adrenomed
Sep 16, 2020 Adrenomed will participate in the virtual J.P. Morgan 39th Annual Healthcare Conference 2021. Join us for #HealthcarePartneringWeek on January 11-15, where we’ll …See details»
Adrenomed - Contacts, Employees, Board Members, Advisors
Adrenomed is a privately-financed, clinical-stage biopharmaceutical company.See details»
2021 – Adrenomed
Aug 23, 2021 Adrenomed Announces Participation in Scientific and Industry Events in September and October 2021 Hennigsdorf/Berlin (Germany), August 30th, 2021 – Adrenomed …See details»
Adrenomed AG (@adrenomed) / Twitter
Nov 16, 2018 Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Its mission is to rescue vascular integrity in order to save the lives...See details»
Adrenomed - Profiles & Contacts - Crunchbase
Adrenomed is a privately-financed, clinical-stage biopharmaceutical company.See details»
About AdrenoMed AG - pharmiweb.jobs
Apr 11, 2024 AdrenoMed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team …See details»